Literature DB >> 22654429

Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection.

Hyuk Soon Choi1, Hoon Jai Chun, Sang Hoon Park, Bora Keum, Yeon Seok Seo, Yong Sik Kim, Yoon-Tae Jeen, Soon Ho Um, Hong Sik Lee, Chang Duck Kim, Ho Sang Ryu.   

Abstract

AIM: To compare the effectiveness of sequential therapy for Helicobacter pylori (H. pylori) infection with that of triple therapy of varying durations.
METHODS: The 460 patients enrolled in this study had H. pylori-associated gastritis or a gastric or duodenal ulcer. After screening, H. pylori-infected patients were randomly assigned to receive either conventional triple therapy for 7, 10 or 14 d, or a new 10-d sequential therapy. Each of the 4 treatment groups included 115 patients. The outcomes of eradication therapy were assessed 4 wk after treatment by the urea breath test and histology.
RESULTS: The overall eradication rate was 81.0%, and eradication rates were 75.7% for 7-d conventional triple therapy, 81.9% for 10-d conventional triple therapy, 84.4% for 14-d conventional triple therapy, and 82.0% for 10-d sequential therapy. Neither intention-to-treat analysis nor per protocol analysis showed significant differences in eradication rates using sequential therapy or the standard triple therapy (P = 0.416 and P = 0.405, respectively).
CONCLUSION: There are no significant differences between 10-d sequential eradication therapy for H. pylori and any duration of standard triple treatment in Korean patients.

Entities:  

Keywords:  Duodenal ulcer; Gastric ulcer; Gastritis; Helicobacter pylori; Sequential therapy; Triple therapy

Mesh:

Substances:

Year:  2012        PMID: 22654429      PMCID: PMC3353372          DOI: 10.3748/wjg.v18.i19.2377

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  43 in total

1.  A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.

Authors:  X Calvet; N García; T López; J P Gisbert; E Gené; M Roque
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

2.  [Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].

Authors:  Jae Yeon Kim; Na Young Kim; Sung Jung Kim; Gwang Ho Baik; Gwang Ha Kim; Jung Mogg Kim; Ryoung Hee Nam; Hong Bin Kim; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal:  Korean J Gastroenterol       Date:  2011-04

3.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.

Authors:  E Gené; X Calvet; R Azagra; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2003-05-01       Impact factor: 8.171

Review 4.  The importance of efflux pumps in bacterial antibiotic resistance.

Authors:  M A Webber; L J V Piddock
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

5.  Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea.

Authors:  Nayoung Kim; Jung Mogg Kim; Chung Hyun Kim; Young Soo Park; Dong Ho Lee; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

6.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

7.  Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.

Authors:  Y S Kim; S J Kim; J H Yoon; K T Suk; J B Kim; D J Kim; D Y Kim; H J Min; S H Park; W G Shin; K H Kim; H Y Kim; G H Baik
Journal:  Aliment Pharmacol Ther       Date:  2011-09-19       Impact factor: 8.171

8.  Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.

Authors:  Hong Sang Oh; Dong Ho Lee; Ji Yeon Seo; Yu Ri Cho; Nayoung Kim; Sook Hyang Jeoung; Jin Wook Kim; Jin Hyeok Hwang; Young Soo Park; Sang Hyub Lee; Cheol Min Shin; Hyun Jin Cho; Hyun Chae Jung; In Sung Song
Journal:  J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 4.029

9.  Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe.

Authors:  S Koletzko; F Richy; P Bontems; J Crone; N Kalach; M L Monteiro; F Gottrand; D Celinska-Cedro; E Roma-Giannikou; G Orderda; S Kolacek; P Urruzuno; M J Martínez-Gómez; T Casswall; M Ashorn; H Bodanszky; F Mégraud
Journal:  Gut       Date:  2006-04-07       Impact factor: 23.059

10.  Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study.

Authors:  Jung H Kwon; Dong H Lee; Byeong J Song; Jung W Lee; Jin J Kim; Young S Park; Nayoung Kim; Sook-Hyang Jeong; Jin-Wook Kim; Sang H Lee; Jin H Hwang; Hyun C Jung; In S Song
Journal:  Helicobacter       Date:  2010-04       Impact factor: 5.753

View more
  15 in total

1.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.

Authors:  Nabil Ben Chaabane; Hamad Saadoon Al-Adhba
Journal:  Indian J Gastroenterol       Date:  2015-02-28

3.  Current Consensus and Remaining Questions Regarding the Diagnosis and Treatment of Helicobacter pylori Infection.

Authors:  William D Chey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-09

Review 4.  Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.

Authors:  Javier Molina-Infante; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 5.  Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence.

Authors:  Vikram Kate; Raja Kalayarasan; Nilakantan Ananthakrishnan
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 6.  Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.

Authors:  Ariolana A Dos Santos; Adriana A Carvalho
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

7.  High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.

Authors:  Jung Won Lee; Nayoung Kim; Ryoung Hee Nam; Jung Mogg Kim; Jong Youn Park; Sun Min Lee; Joo Sung Kim; Dong Ho Lee; Hyun Chae Jung
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

8.  Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.

Authors:  Hye-Kyung Jung; Seung Joo Kang; Yong Chan Lee; Hyo-Joon Yang; Seon-Young Park; Cheol Min Shin; Sung Eun Kim; Hyun Chul Lim; Jie-Hyun Kim; Su Youn Nam; Woon Geon Shin; Jae Myung Park; Il Ju Choi; Jae Gyu Kim; Miyoung Choi
Journal:  Korean J Intern Med       Date:  2021-06-08       Impact factor: 2.884

Review 9.  Treatment of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis.

Authors:  Sang Wook Lee; Hyun Jung Kim; Jae Gyu Kim
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

Review 10.  Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.

Authors:  Luigi Gatta; Nimish Vakil; Dino Vaira; Carmelo Scarpignato
Journal:  BMJ       Date:  2013-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.